Key result
Whole-body FDG PET underperforms MRI and chest CT in detecting local recurrence and lung metastases.
Why the study?
The ability of whole-body 18F-fluorodeoxyglucose positron emission tomography (FDG PET) to identify local recurrence and pulmonary metastases in soft-tissue sarcoma patients after treatment was evaluated.
Does FDG PET accurately detect local recurrence and pulmonary metastases compared to MRI and CT in patients with treated soft-tissue sarcomas?
Observational (n=62)
Does FDG PET accurately detect local recurrence and pulmonary metastases compared to MRI and CT in patients with treated soft-tissue sarcomas?
FDG PET can identify both local and distant recurrence of soft-tissue sarcomas as a one-step procedure, though MRI and CT remain necessary for accurate disease extent definition.
Answers are grounded in this paper and cite their sources.
FDG PET's lower sensitivity cautions against replacing MRI or CT; leaves open its role as one-step surveillance in treated sarcomas.
We performed a retrospective analysis to evaluate the ability of whole-body 18F-fluorodeoxyglucose positron emission tomography (FDG PET) to identify local recurrence and pulmonary metastases in patients with soft-tissue tumours after treatment. We compared the results of FDG PET with those of MRI for the detection of local recurrence, and with CT of the chest for pulmonary metastases. We assessed 62 patients of mean age 51 years, who had 15 types of soft-tissue sarcoma, after a mean follow-up of 3 years 2 months. For the detection of local disease, 71 comparisons showed that the sensitivity and specificity of FDG PET were 73.7% and 94.3%, respectively; there were 14 true-positive and five false-negative results. MRI had a sensitivity and specificity of 88.2% and 96.0% respectively. For the identification of lung metastases, 70 comparisons showed that the sensitivity and specificity of FDG PET were 86.7% and 100%, with 13 true-positive results and two false-negative results. CT of the chest had a sensitivity and specificity of 100% and 96.4%. Thirteen other sites of metastases were identified by FDG PET. FDG PET can identify both local and distant recurrence of tumour as a one-step procedure and will detect other metastases. It seems that all three methods of imaging are needed to define accurately the extent of disease, both at initial staging and during follow-up.
No takes yet. Share an insight, caveat, or question.
Lucas et al. (1998) conducted an observational in Soft-tissue sarcomas (n=62). 18F-fluorodeoxyglucose positron emission tomography (FDG PET) vs. MRI and chest CT was evaluated on Detection of local recurrence and pulmonary metastases. Whole-body FDG PET detected local recurrence with 73.7% sensitivity and lung metastases with 86.7% sensitivity, compared to 88.2% for MRI and 100% for chest CT, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: